Traditional MedicareCoverageHigh impact
Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
Medicare/CMS - LCD·Orthopedics, Pain Management, Sports Medicine +2 more·Local Coverage Determination
Effective date
Jul 16, 2026
We identified it
Jul 16, 2026
Summary
This is a NEW Local Coverage Determination (LCD L39128) from Palmetto GBA that establishes coverage policy for amniotic and placental-derived product injections and applications used for musculoskeletal indications (non-wound). The policy is effective 7/16/2026 and applies to both Medicare Part A and Part B claims within Palmetto GBA's jurisdiction. Billing teams must immediately obtain and review the full policy text to understand coverage criteria, documentation requirements, and any prior authorization mandates.
Action Required
CRITICAL - By 7/10/2026 (Policy effective 7/16/2026): (1) Billing team must immediately access and download the FULL policy text from https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39128&ver=15 to identify specific CPT/HCPCS codes, documentation requirements, and prior authorization mandates that are NOT included in this summary. (2) Update billing software and claim submission workflows to implement any coverage restrictions or prior auth requirements identified in the full policy. (3) Notify all providers performing amniotic/placental-derived product injections of new coverage requirements and documentation standards. (4) Review current patient cases to identify any pending claims that may be affected. (5) Implement any required prior authorization processes in practice management system before 7/16/2026 effective date. (6) Train billing, clinical, and front desk staff on new requirements. NOTE: This summary lacks specific billing codes and clinical criteria because the full policy text was not provided. Immediate review of the complete LCD document is mandatory to ensure compliant claim submission and avoid denials.